Skip to main content
Daesung Microbiological Labs. Co. Ltd logo

Daesung Microbiological Labs. Co. Ltd — Investor Relations & Filings

Ticker · 036480 ISIN · KR7036480002 KO Manufacturing
Open in API
Filings indexed 126 across all filing types
Latest filing 2022-03-08 Proxy Solicitation & In…
Country KR South Korea
Listing KO 036480

About Daesung Microbiological Labs. Co. Ltd

https://eng.dsmbio.co.kr/

Daesung Microbiological Labs. Co., Ltd. is a company specializing in the development, manufacturing, and distribution of animal pharmaceuticals. Established in 1968, it is a leading vaccine manufacturer operating under KVGMP (Korean Veterinary Good Manufacturing Practice) standards. The company's product portfolio includes a comprehensive range of vaccines, antibiotics, parasiticides, and nutritional supplements. These products are designed for the health and well-being of livestock such as swine, bovine, and poultry, as well as for companion animals like canines. Daesung Microbiological Labs is committed to achieving disease-free livestock through continuous research and technological innovation in animal health.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Daesung Microbiological Labs. It contains the agenda for the meeting, details on director appointments, and comprehensive financial statements (balance sheet, income statement, etc.) provided as reference materials for shareholders to review prior to the meeting. This type of document is a standard Proxy Solicitation & Information Statement, as it provides shareholders with the necessary information to vote on agenda items.
2022-03-08 Korean
주주총회집중일개최사유신고
AGM Information Classification · 1% confidence The document is a formal notification filed with the Korea Exchange (KRX) regarding the company's decision to hold its Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the scheduling constraints and acknowledges the regulatory guidance regarding AGM dispersion. Since this is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves, a proxy statement, or a voting result, it falls under the general regulatory filing category.
2022-03-08 Korean
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Daesung Microbiological Labs. It outlines the date, location, agenda items (financial statement approval, director appointments, and remuneration limits), and details of the board's resolution. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2022-02-22 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (Daesung Microbiological Labs) announcing a significant change (greater than 15% or 30%) in its financial results (revenue, operating profit, net income) compared to the previous fiscal year. This is a standard regulatory disclosure requirement in the Korean market (DART system) for material financial changes. Since it provides the initial announcement of financial performance figures before the final audit is completed, it falls under the category of an Earnings Release (ER). FY 2021
2022-02-08 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 1% confidence The document is a formal announcement regarding a decision on cash dividends ('현금ㆍ현물배당 결정'). It specifies the dividend amount per share, the total dividend amount, the record date, and the approval process. This aligns perfectly with the definition for 'Notice of Dividend Amount' (DIV).
2022-02-08 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from a Korean company (Daesung Microbiological Labs) regarding a correction to a previously disclosed 'Single Sales/Supply Contract'. It details the adjustment of contract amounts based on actual performance at the end of the contract period. Since this is a specific regulatory disclosure regarding a material contract update that does not fit into categories like financial reports, dividends, or M&A, it falls under the general regulatory filing category.
2021-12-30 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.